Conclusions. Urinary TGF-b1 excretion was increased in patients with MGN, and high excretion indicated Background. Human idiopathic membranous glomerulonephritis (MGN ) has a highly variable clinical intrarenal sclerosing/fibrosing processes and progressive clinical course. Measuring urinary TGF-b1 may be course and factors determining its outcome are poorly known. Since transforming growth factor-b1 ( TGF-useful in the assessment of the progression of disease and the effects of treatment in MGN. b1) has an essential role in renal fibrogenesis, we studied the possibility to use urinary excretion of TGF-
IgA glomerulonephritis, and seven proteinuric patients Introduction (with non-progressive diseases) using a novel, double antibody enzyme immunoassay. The results were com-A puzzling feature of glomerulonephritides (GN ) is pared with renal morphology and clinical indices of the irrevocably progressive course in a considerable activity of MGN over 12 months.
proportion of the patients, resulting in end-stage renal Results. The median urinary TGF-b1 excretion (pg/mg failure. In general, the tendency towards progression creatinine) was significatly higher (1730; range is primarily related to the morphological type of the 60-16970) in MGN patients than in the healthy conglomerular lesion although the evolution may be highly trols (300; 30-1330; P<0.0001). In renal allograft variable even within one category of disease. A typical recipients the excretion was 840 (250-3440; P<0. 0001 example is idiopathic membranous glomerulonephritis vs healthy controls), in IgA GN it was 1130 (30-4910; (MGN ) where the clinical course ranges from persist-P=0.039), and in proteinuric patients it was 39 ent remission to relapsing disease activity and progress-(29-165; P=NS). In MGN but not in the proteinuric ive renal failure [1] [2] [3] . Even in the early phases of this controls or renal allograft recipients, urinary TGF-b1 disease inflammatory changes may be detected in intercorrelated with urinary albumin excretion (r=0.86, stitial areas [4] and progressive disease is characterized P<0.0001) but no correlation with renal function or by accumulation of extracellular matrix ( ECM ) comthe duration of the disease was found. Urinary TGFponents into the mesangial areas, often thickening of b1 at renal biopsy correlated with interstitial cellular the glomerular basement membrane [5] and almost inflammation and its excretion 1 year before the biinvariably increasing interstitial fibrosis and tubular opsy correlated with indices of sclerosis/fibrosis.
atrophy [6 ] . Immunosuppressive therapy significantly decreased
The pathogenesis of glomerular sclerosis and interurinary TGF-b1 from 2800 (1610-16960) to 840 stitial fibrosis involves action of numerous cytokines (170-1600) pg/mg creatinine (P=0.028). Patients with and growth factors [7] . The production of these medipersistent nephrotic syndrome and/or declining renal ators may be triggered either by immunological or function had a higher initial TGF-b1 excretion (median non-immunological (metabolic) factors [7] . During the 3680; 1830-7420 pg/mg creatinine) than those entering past few years several studies have strongly suggested partial or complete remission (1060; 60-1960; P= a unique role for transforming growth factor-b ( TGF-0.003) within 12 months from sampling. 
Subjects and methods
undiluted urine samples were incubated in the wells at 4°C overnight. The TGF-b1 bound into the wells was then
Patients with membranous glomerulonephritis
detected with polyclonal IgG-type sheep antibodies to TGFb1 (1 ng/well, for 2 h at 37°C ) (Jansen Biochemica, USA) The study population comprised 41 patients with idiopathic which were labelled with alkaline phosphatase. Akaline MGN ( Table 1) biopsied and followed up at the Helsinki phosphatase activity was determined using p-nitroUniversity Central Hospital. In 11 of the patients urinary phenylphosphate as substrate in 1 mol/l diethanolamine-0.5 and serum samples were obtained at the first renal biopsy, mol/l MgCl 2 buffer (pH 10, 30 min at 37°C ). Natural, human in 17 patients at rebiopsy, and in 13 patients with previously TGF-b1 (R&D Systems, UK ) served as standard. Detection diagnosed (biopsied) MGN during an outpatient visit. The limit of the assay was 10 ng/l. The intra-assay and interassay median duration of disease (calculated from the first renal coefficients of variation were 5.9 and 8.1% respectively. The biopsy) at sampling was 19 (0-272) months.
recoveries of added (50 and 100 ng/l ) TGF-b1 ranged from 87 to 103%. For calculations TGF-b1 values below the detection limit were assigned as 5 ng/l. To compensate for
Controls
alterations caused by varying urinary concentration the excretion of TGF-b1 was related to concomitant urinary The control population consisted of 25 healthy subjects who were studied as outpatients ( Table 1 ). The following patients creatinine (crea). 
Changes in urinary TGF-b1 from day to day
To examine the stability of urinary TGF-b1 excretion from day to day, six persons collected 24-h urines over 3 consecutive days.
Other laboratory tests
Renal function was assessed by serum creatinine (normal values from 50 to 130 mmol/l ) and GFR (51Cr-EDTAclearance or 24-hour creatinine clearance, normal value over 80 ml/min/1.73 m2). Serum creatinine, albumin as well as the urinary protein, albumin, and creatinine were measured using routine methods. 
Renal biopsies
Biopsies, obtained using 14G BioptyA needles (Manan Urinary TGF-b1 in patients and control subjects Medical Poducts, Noorthbrook, IL, USA), were processed as described previously [23] . The lesions were classified using Figure 2 depicts the urinary TGF-b1 excretions. an international system [24] and scored throughout the study Healthy control subjects had a median TGF-b1 exby the same investigator (TT ) who was unaware of the cretion of 300 (30-1330) pg/mg crea (220 ng/l ) and urinary TGF-b1 concentrations. Twenty patients with MGN patients with MGN an excretion of 1730 (60-16970) had their urinary TGF-b1 excretion compared with morpho-pg/mg crea (1200 ng/l ) (P<0.0001 vs normal controls).
logical alterations in simultaneously obtained renal biopsies.
In patients having stable renal allografts the excretion crea (970 ng/l ) (P=0.039), and in proteinuric controls
The following morphological alterations were scored semiquantitatively (scale 0, 1, 2, and 3): increased thickness of the glomerular basement membrane, amount of mesangial matrix, tubular atrophy, interstitial fibrosis, interstitial cellular infiltration, and the sum of scores for mesangial matrix and interstitial fibrosis (assigned as sclerosis index).
Statistical methods
Values are expressed as medians (range) unless otherwise indicated. As the distribution of TGF-b1 values, corrected by urinary creatinine content was skew, non-parametric analysis of variance (ANOVA; Kruskall-Wallis) was employed for repeated measurements. Comparisons between two groups were performed with Mann-Whitney U test. The effect of treatment was evaluated with Wilcoxon's signed rank test. Simple and multiple linear regression analyses were used to study interrelationships between various parameters. Comparison between renal morphology and urinary TGFb1 was done after logarithmic conversion of the TGF-b1 values. The calculations were performed using SystatA (Systat Inc., USA) and StatView 512+@ (BrainPower Inc., USA) softwares, and P values less than 0.05 were considered significant. constant from day to day.
Results

Changes in urinary TGF-b1 excretion from day to day
biopsy), serum albumin or GFR was found. However, there was a relationship between urinary albumin and TGF-b1 excretion (r=0.86, P<0.0001) in MGN. Similar correlation was also observed in patients with IgA GN (r=0.7, P=0.002) but no correlation was found in the proteinuric control patients or renal allograft recipients (who had no proteinuria at all ).
Urinary TGF-b1 and morphological findings
When urinary TGF-b1 was compared with renal morphology in simultaneously obtained biopsies it appeared that the excretion correlated with the degree of interstitial cellular inflammation but not with other variables (Table 2 ). However, in seven patients urinary 
Immunosuppressive therapy and urinary TGF-b1
MGN was analysed in 14 patients ( Figure 4 ). They all had the initial urinary TGF-b1 measured at or within Six patients had the urinary TGF-b1 excretion studied 12 months of diagnosis (renal biopsy), the nephrotic before and after immunosuppressive therapy (i.v. plus syndrome (protein excretion exceeding 3 g/24 h), oral methylprednisolone or cytotoxic drugs), indication and normal or nearly normal renal function (serum for the therapy typically being deteriorating renal creatinine less than 130 mmol/l, GFR over function and/or persistent nephrotic syndrome and 60 ml/min/1.73 m2). The patients were divided into total duration of treatment varying from 6 to 8 months two groups according to the clinical status at 12 (Figure 3) . Before the therapy the median TGF-b1 months after the initial TGF-b1 assay: (a) persistent excretion was 2800 (1610-16960) pg/mg crea and it nephrotic syndrome and/or declining GFR (GFR decreased during 12 months to 840 (170-1600) pg/mg decreasing below the normal reference value by more crea (P=0.028). Proteinuria decreased from 13.3 than 20%), or (b) remitting disease when the patient (6.3-27.5) to 7.7 (1.4-12.8) g/24 h (P=0.023) and entered either partial (urinary protein excretion serum creatinine from 176 (83-303) to 143 (71-165) 0.15-2.9 g/24 h) or complete remission (proteinuria mmol/l (P=0.086) during the therapy. less than 0.15 g/24 h with normal GFR). In group (a) (n=8) with a baseline protein excretion Urinary TGF-b1 and clinical course of MGN of 8.4 (5.6-11.4) g/24 h and age 49 (25-66) years the initial urinary TGF-b1 excretion was 3680 (1830-7420) The usefulness of urinary TGF-b1 assay in predicting the short-term clinical course of recently diagnosed pg/mg crea, while in group (b) (n=6) with a protein MGN (where it was actually decreased) [27] . Renal allograft recipients studied by Coupes et al. [28] had elevated plasma levels of TGF-b1 but their urinary TGF-b1 excretion was comparable with the normal subjects as it also was in MGN patients. Our findings may differ from the above human studies for several reasons. The results of Kanai et al. [27] are not directly comparable because many patients received prednisolone treatment and possibly had rather inactive diseases (as judged from minimal proteinuria). TGF-b molecules, synthesized as precursors are cleaved to monomers and associated with the latency associated protein [9] . Activation of this latent complex is caused by acidification, alkalinization, heating, or proteases [9, 29] , and in previous studies the methods for activation of urinary TGF-bs have been variable (if done at all ). Finally, differences in the antibodies and standards used in assays may explain the disparities between the studies.
Urinary TGF-b1 correlated with albumin excretion in MGN (and IgA GN as well ) whereas proteinuric TGF-b1 excretion. These findings suggests that the elevated TGF-b1 excretion in MGN is not simply excretion of 5.0 (3.5-17.0) g/24 h (P=NS vs group explained by an increased glomerular permeability of (a), and age 40 (26-69) years (P=NS vs group (a), proteins although this issue warrants further studies. the initial urinary TGF-b1 excretion was 1060
Proteinuria reflects the imunological activity (i.e., (60-1960) pg/mg crea (P=0.003 vs group (a)).
the size and location of electron-dense deposits) of In these patients with the nephrotic syndrome the MGN [25] and its quantity is a rough indicator of the clinical status at 12 months correlated with the initial severity and prognosis of this disease [2] . It is possible urinary TGF-b1 excretion (r=0.79, P=0.002) but not that active MGN leading to and toxic effects of long with the baseline proteinuria (r=0.1, P=NS, univari-standing proteinuria on mesangial and tubular cells ate analysis). Also in a multiple regression analysis [30] are related to increased urinary TGF-b1 in MGN. where the clinical status at 12 months was the depend-It is also theoretically possible that reduced absorption ent variable, the short-term clinical course correlated of filtered TGF-b1 may have contibuted to the elevated highly significantly with the initial urinary TGF-b1 urinary values. (P=0.004) but not with the baseline proteinuria or age.
We did not study the production of TGF-b1 in the renal tissue. However, experimental and human studies have demonstrated that renal injury is associated with Discussion an increased expression of TGF-b by glomerular mesangial [12, 29, 31 ] and epithelial cells [32] as well as by the tubulointerstitial compartment [33] . In adriamycin The present study focuses on MGN, a prototype of an immune-mediated, slowly progressive glomerulo-nephropathy interstitial inflammatory cells express TGF-b1 [34] . Platelets contain high concentrations of nephritis in which the clinical and morphological course is unpredictable [2, 25] . It appeared that the TGF-b [7, 8] but their depletion does not modulate renal injury in experimental glomerulonephritis [8] . majority of patients had an elevated urinary TGF-b1, highly increased excretion being associated with a Monocytes may not only produce but also express receptors for TGF-b1 whereby it can affect monocytic progressive renal disease.
Urinary TGF-b excretion has previously been infiltration and their secretion of TNF-a and IL-1 [35] . Thus our findings together with above studies studied only in some experimental and clinical settings. Rabbit crescentic nephritis, induced by glomerular strongly suggest that the most probable sources of urinary TGF-b1 are renal parenchymal and/or invadbasement membrane antibodies, was associated with an increased TGF-b excretion which peaked 7 days ing cells.
In the present study there was a relationship between after the induction of the disease and correlated with its severity [26 ] . In humans the urinary TGF-b excre-urinary TGF-b1 and interstitial inflammation which may point to a role for inflammation as a trigger of tion was significantly increased in focal segmental glomerulosclerosis only, slightly elevated in systemic TGF-b1 synthesis. However, a single TGF-b1 value may not reliably reflect the duration of inflammation lupus erythematosus but not in IgA nephropathy or 
